From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer
Open Access
- 1 January 2021
- journal article
- review article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 11 (3) , 1310-1325
Abstract
The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) immune checkpoint proteins hold promise as diagnostic, prognostic, and therapeutic targets for precision oncology. By restoring antitumor T cell surveillance, the high degree of effectiveness of the immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment. However, the majority of patients (65-80 %) treated with ICIs experience significant side effects, called immune-related adverse events (irAEs), resulting in autoimmune damage to various organs. Therefore, broadening the clinical applicability of these treatments to all cancer types requires an improved understanding of the mechanisms linking cancer immune evasion and autoimmunity. The thyroid is the endocrine gland the most frequently involved in autoimmunity and cancer, the growing incidence of which is raising serious public health issues worldwide. In addition, the risk of developing thyroid cancer is increased in patients with autoimmune thyroid disease and thyroid dysfunction is one of the most common irAEs, especially with PD‑1/PD-L1 blockade. Therefore, we chose the thyroid as a model for the study of the link between autoimmunity, irAEs, and cancer. We provide an update into the current knowledge of the PD‑1/PD-L1 axis and discuss the growing interest of this axis in the diagnosis, prognosis, and management of thyroid diseases within the context of autoimmunity and cancer, while embracing personalized medicine.Keywords
This publication has 100 references indexed in Scilit:
- Molecular mechanisms of T cell co-stimulation and co-inhibitionNature Reviews Immunology, 2013
- Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulationEndocrine-Related Cancer, 2012
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- The Bethesda System for Reporting Thyroid Cytopathology: A Meta-AnalysisActa Cytologica, 2012
- Programmed Death-1+ T Cells and Regulatory T Cells Are Enriched in Tumor-Involved Lymph Nodes and Associated with Aggressive Features in Papillary Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2012
- Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine‐Needle Aspiration State of the Science ConferenceDiagnostic Cytopathology, 2008
- Tag SNP screening of the PDCD1 gene for association with Graves’ diseaseClinical Endocrinology, 2007
- Mechanisms of Immune Evasion by Tumors2006
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Thyroid Autoimmune DiseaseThe American Journal of Pathology, 2001